Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23488532 | 1.00 | CA2 (0.47) | CA2CA9CA1LGALS3LGALS8 | |
| SCHEMBL23488729 | 0.87 | CA2 (0.50) | CA2CA9CA1LGALS3LGALS8 | |
| SCHEMBL23488551 | 0.87 | LGALS3 (0.43) | LGALS3MEN1KMT2A | |
| SCHEMBL23488531 | 0.85 | CA2 (0.45) | CA2CA9CA1LGALS3LGALS8 | |
| SCHEMBL23488662 | 0.83 | LGALS8 (0.47) | LGALS3LGALS8PDCD1CD274APP | |
| SCHEMBL23488661 | 0.82 | LGALS8 (0.56) | LGALS3LGALS8PDCD1CD274APP | |
| SCHEMBL23488440 | 0.81 | CA2 (0.52) | CA2CA9CA1LGALS3LGALS8 | |
| SCHEMBL23488781 | 0.81 | CA2 (0.52) | CA2CA9CA1LGALS3LGALS8 | |
| SCHEMBL23488325 | 0.80 | CA2 (0.49) | CA2CA9CA1LGALS3LGALS8 | |
| SCHEMBL23488456 | 0.80 | CA2 (0.47) | CA2CA9CA1LGALS3LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | CA2 1099/4885CA9 906/4885CA1 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.